Clinical Trial Update: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

This Phase 2 study evaluated the safety, pharmacokinetics, and brain amyloid plaque clearance of ABBV-916 in adults aged 50 to 90 with early Alzheimer's disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABBV-916

Snippet

Sponsor: AbbVie | Conditions: Alzheimer's Disease (AD) | Phase 2 | Status: COMPLETED